HUMA

SEC source: 0001818382-25-000016 · wk-form4_1737668047.xml · derivative · entry 1

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,101

Underlying: Common Stock · 283,101 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-25-000018 · wk-form4_1737668069.xml · derivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 1,130,311

Underlying: Common Stock · 1,130,311 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-25-000021 · wk-form4_1737668104.xml · derivative · entry 1

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,101

Underlying: Common Stock · 283,101 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-25-000015 · wk-form4_1737668036.xml · derivative · entry 1

Parikh Shamik J · CIK 0001916853 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,101

Underlying: Common Stock · 283,101 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-25-000019 · wk-form4_1737668079.xml · derivative · entry 1

Cao Yang · CIK 0001946538 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,101

Underlying: Common Stock · 283,101 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-24-000231 · wk-form4_1734732576.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-24-000230 · wk-form4_1734732566.xml · derivative · entry 1

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-24-000228 · wk-form4_1734732546.xml · derivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 2,625

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-24-000229 · wk-form4_1734732556.xml · derivative · entry 1

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-24-000216 · wk-form4_1733346343.xml · nonDerivative · entry 1

Constantino Michael T. · CIK 0001817285 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,950

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,730,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000206 · wk-form4_1732147338.xml · nonDerivative · entry 3

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,730,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,992,253

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000206 · wk-form4_1732147338.xml · nonDerivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,992,253

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000214 · wk-form4_1732192270.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,851

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000213 · wk-form4_1732192208.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 243,851

F1 · shares: This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 2,419,712

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000206 · wk-form4_1732147338.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 2,419,712

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000189 · wk-form4_1726519004.xml · derivative · entry 2

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 1,200 shares

Expires 2032-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000189 · wk-form4_1726519004.xml · nonDerivative · entry 1

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000184 · wk-form4_1726091430.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,230,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000185 · wk-form4_1726091522.xml · nonDerivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,230,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · derivative · entry 6

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,021

Underlying: Common Stock · 2,479 shares

Expires 2033-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · derivative · entry 5

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,979

Underlying: Common Stock · 4,521 shares

Expires 2032-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 4

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,207

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 3

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 2

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,276

F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000186 · wk-form4_1726091586.xml · nonDerivative · entry 1

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000184 · wk-form4_1726091430.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,519,558

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000185 · wk-form4_1726091522.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,519,558

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,677,262

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000167 · wk-form4_1724971784.xml · nonDerivative · entry 3

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,677,262

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000177 · wk-form4_1725395025.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,054

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase.

SEC source: 0001818382-24-000175 · wk-form4_1725394624.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 242,054

F1 · shares: This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,029,374

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000167 · wk-form4_1724971784.xml · nonDerivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,029,374

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,306,464

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000165 · wk-form4_1724971323.xml · derivative · entry 4

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,389 shares

Expires 2025-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000165 · wk-form4_1724971323.xml · nonDerivative · entry 2

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000165 · wk-form4_1724971323.xml · nonDerivative · entry 1

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000167 · wk-form4_1724971784.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,306,464

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000158 · wk-form4_1723752500.xml · nonDerivative · entry 1

Constantino Michael T. · CIK 0001817285 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,350

SEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · derivative · entry 3

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,389 shares

Expires 2025-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · nonDerivative · entry 1

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000132 · wk-form4_1718655055.xml · derivative · entry 1

Bamforth John Philip · CIK 0002026341 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000137 · wk-form4_1718655110.xml · derivative · entry 1

Jones Keith Anthony · CIK 0002026411 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000136 · wk-form4_1718655099.xml · derivative · entry 1

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000140 · wk-form4_1718655145.xml · derivative · entry 1

Seimetz Diane · CIK 0001930980 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000133 · wk-form4_1718655066.xml · derivative · entry 1

Brown Emery N. · CIK 0001878691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000138 · wk-form4_1718655122.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.